JL Chan, MJ Abrahamson - Mayo Clinic Proceedings, 2003 - mayoclinicproceedings.com Type 2 diabetes mellitus is a chronic metabolic disorder associated with high
morbidity and mortality from long- term microvascular and macrovascular
complications. Evidence from randomized controlled trials indicates that ... Cited by 76 - Related articles - View as HTML - BL Direct - All 12 versions
MC Riddle - Endocrinology and metabolism clinics of North America, 2005 - Elsevier We have long known, but now understand more fully that type 2 diabetes is
common, complex, and as treated presently, leads to severe medical consequences.
In type 1 diabetes, hyperglycemia is the leading cause of harm. In type 2 ... Cited by 67 - Related articles - All 3 versions
- ►columbiauniversity.org [PDF] B Kimmel, SE Inzucchi - Clinical Diabetes, 2005 - Am Diabetes Assoc Type 2 diabetes is a multifactorial metabolic disease characterized by
abnormalities at multiple organ sites. These defects include insulin resistance
and insulin deficiency. 1,2 The former is primarily represented by ... Cited by 46 - Related articles - All 5 versions
SD West, DJ Nicoll, TM Wallace, DR Matthews … - British Medical Journal, 2007 - thorax.bmj.com Results: Results are expressed as mean (SD). CPAP improved the Epworth
sleepiness score significantly more in the therapeutic group than in the placebo
group (–6.6 (4.5) vs –2.6 (4.9), p = 0.01). The maintenance of ... Cited by 43 - Related articles - BL Direct - All 5 versions
IW Campbell - International journal of clinical practice, 2004 - interscience.wiley.com Patients with type 2 diabetes have dual defects: insulin resistance and β-cell
dysfunction. Thiazolidinediones (TZDs), a new class of oral drugs used for the
treatment of type 2 diabetes, reduce insulin resistance via an action on ... Cited by 19 - Related articles - BL Direct - All 5 versions
- ►dvdres.com [PDF] JHB Scarpello, H Howlett - Diabetes & Vascular Disease Research, 2008 - dvr.sagepub.com Abstract M etformin is now established as a first-line antidiabetic therapy for
the management of type 2 diabetes. Its early use in treatment algo- rithms is
supported by lack of weight gain, low risk of hypoglycaemia and its mode of ... Cited by 17 - Related articles - All 8 versions
M Feinglos, G Dailey, W Cefalu, K Osei, J … - Diabetes research and clinical practice, 2005 - Elsevier The addition of glipizide GITS to metformin gave significantly greater
improvements in mean A 1c and FPG from baseline to endpoint than placebo
addition (p < 0.0002). Significantly more patients in the glipizide GITS ... Cited by 12 - Related articles - All 8 versions
M Monami, C Lamanna, N Marchionni, E … - Diabetes research and clinical practice, 2008 - Elsevier Metformin is recommended as first-line treatment in type 2 diabetic patients.
Several agents can be used as add-on treatments in metformin monotherapy
failure. Most available clinical trials on the hypoglycemic efficacy of ... Cited by 12 - Related articles - All 26 versions
AG Arno, JF NADAL, MM CASES - Medicina clinica(Ed. impresa), 2004 - cat.inist.fr Criterios de control y pautas de tratamiento combinado en la diabetes tipo
2. ActualizaciÓn 2004. Alberto Goday ARNO, Josep Franch ... Cited by 16 - Related articles - All 3 versions
- ►adisonline.com [PDF] G Charpentier, JP Riveline, D Dardari, M … - Drugs, 2006 - ingentaconnect.com Numerous prospective studies support the concept of postprandial glycaemia
Abstract (PPG) as a risk factor for cardiovascular diseases (CVDs) in
individuals with impaired glucose tolerance (IGT). A meta-analysis has ... Cited by 4 - Related articles - BL Direct - All 7 versions
